All Stories

  1. Global tuberculosis targets and milestones set for 2016–2035: definition and rationale
  2. Measuring performance_Healthcare Access_Quality Index for 195 countries and territories
  3. Evidence-informed policy making at country level: lessons learned from the South African Tuberculosis Think Tank
  4. Transmission events revealed in tuberculosis contact investigations in London
  5. Small contribution of gold mines to the ongoing tuberculosis epidemic in South Africa: a modeling-based study
  6. An explanation for the low proportion of tuberculosis that results from transmission between household and known social contacts
  7. Improving ART programme retention and viral suppression are key to maximising impact of treatment as prevention – a modelling study
  8. Impact of Targeted Tuberculosis Vaccination Among a Mining Population in South Africa: A Model-Based Study
  9. Universal test, treat, and keep: improving ART retention is key in cost-effective HIV control in Uganda
  10. An evaluation of tuberculosis contact investigations against national standards
  11. Wildlife-livestock interactions and risk areas for cross-species spread of bovine tuberculosis
  12. Using Data from Macaques To Predict Gamma Interferon Responses after Mycobacterium bovis BCG Vaccination in Humans: a Proof-of-Concept Study of Immunostimulation/Immunodynamic Modeling Methods
  13. Efficient History Matching of a High Dimensional Individual-Based HIV Transmission Model
  14. A novel blood test for tuberculosis prevention and treatment
  15. A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis
  16. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis
  17. The TB vaccine H56+IC31 dose-response curve is peaked not saturating: Data generation for new mathematical modelling methods to inform vaccine dose decisions
  18. History matching of a complex epidemiological model of human immunodeficiency virus transmission by using variance emulation
  19. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models
  20. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models
  21. The potential impact of BCG vaccine supply shortages on global paediatric tuberculosis mortality
  22. Sex Differences in Tuberculosis Burden and Notifications in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis
  23. Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines
  24. Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy
  25. TIME Impact – a new user-friendly tuberculosis (TB) model to inform TB policy decisions
  26. Coverage of clinic-based TB screening in South Africa may be low in key risk groups
  27. A Systematic Review of Published Respondent-Driven Sampling Surveys Collecting Behavioral and Biologic Data
  28. Time for men to count, too
  29. Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study
  30. Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status
  31. The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa
  32. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: “STROBE-RDS” statement
  33. The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis
  34. Tuberculosis Prevention in South Africa
  35. Risk factors associated with Rift Valley fever epidemics in South Africa in 2008–11
  36. Regarding the effect of cured tuberculosis disease on longevity
  37. To improve our tuberculosis burden estimates we need to learn from each other
  38. Bayesian History Matching of Complex Infectious Disease Models Using Emulation: A Tutorial and a Case Study on HIV in Uganda
  39. Accelerating progress towards tuberculosis elimination: the need for combination treatment and prevention
  40. Modelling the HIV epidemic among MSM in the United Kingdom
  41. The Impact of Antiretroviral Therapy on Mortality in HIV Positive People during Tuberculosis Treatment: A Systematic Review and Meta-Analysis
  42. Using the TIME model in Spectrum to estimate tuberculosis–HIV incidence and mortality
  43. Modeling of Novel Diagnostic Strategies for Active Tuberculosis – A Systematic Review: Current Practices and Recommendations
  44. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries
  45. Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling
  46. Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis
  47. How can mathematical models advance tuberculosis control in high HIV prevalence settings?
  48. Towards elimination in industrialised countries: expanding diagnosis and treatment of LTBI among immigrants [Editorial]
  49. Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings
  50. Looking upstream to prevent HIV transmission
  51. The dual impact of antiretroviral therapy and sexual behaviour changes on HIV epidemiologic trends in Uganda: a modelling study
  52. Estimation of the HIV Basic Reproduction Number in Rural South West Uganda: 1991–2008
  53. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models
  54. The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa
  55. Respondent Driven Sampling: Determinants of Recruitment and a Method to Improve Point Estimation
  56. Predicting the Long-Term Impact of Antiretroviral Therapy Scale-Up on Population Incidence of Tuberculosis
  57. Effect of HSV-2 on population-level trends in HIV incidence in Uganda between 1990 and 2007
  58. Community understanding of respondent-driven sampling in a medical research setting in Uganda: importance for the use of RDS for public health research
  59. Transmission Potential of Rift Valley Fever Virus over the Course of the 2010 Epidemic in South Africa
  60. Heterosexual HIV-1 Infectiousness and Antiretroviral Use
  61. Does the ‘inverse equity hypothesis’ explain how both poverty and wealth can be associated with HIV prevalence in sub-Saharan Africa?
  62. Respondent driven sampling—where we are and where should we be going?: Table 1
  63. Exploratory Space-Time Analyses of Rift Valley Fever in South Africa in 2008–2011
  64. HIV and STI Prevalence and Determinants among Male Migrant Workers in India
  65. HIV Treatment as Prevention: Optimising the Impact of Expanded HIV Treatment Programmes
  66. Exploring the Potential Impact of a Reduction in Partnership Concurrency on HIV Incidence in Rural Uganda
  67. Evaluation of Respondent-driven Sampling
  68. Periodic Active Case Finding for TB: When to Look?
  69. Antiretroviral Treatment Cohort Analysis Using Time-Updated CD4 Counts: Assessment of Bias with Different Analytic Methods
  70. Attempting to explain heterogeneous HIV epidemics in sub-Saharan Africa: potential role of historical changes in risk behaviour and male circumcision
  71. Mathematical models for the study of HIV spread and control amongst men who have sex with men
  72. Population Density, Water Supply, and the Risk of Dengue Fever in Vietnam: Cohort Study and Spatial Analysis
  73. Attaining realistic and substantial reductions in HIV incidence: model projections of combining microbicide and male circumcision interventions in rural Uganda
  74. Rift Valley Fever Epidemiology, Surveillance, and Control: What Have Models Contributed?
  75. Antiretroviral therapy and sexual behavior in Uganda: a cohort study
  76. Calibrating Models in Economic Evaluation
  77. Evaluation of the role of location and distance in recruitment in respondent-driven sampling
  78. The role of the natural epidemic dynamics and migration in explaining the course of the HIV epidemic in rural Uganda: a modelling study
  79. Infectiousness of HIV-infected homosexual men in the era of highly active antiretroviral therapy
  80. Polygyny and symmetric concurrency: comparing long-duration sexually transmitted infection prevalence using simulated sexual networks
  81. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention
  82. Do behavioural differences help to explain variations in HIV prevalence in adolescents in sub-Saharan Africa?
  83. Concurrency is more complex than it seems
  84. Strong Association Between In-Migration and HIV Prevalence in Urban Sub-Saharan Africa
  85. Male Circumcision for HIV Prevention in High HIV Prevalence Settings: What Can Mathematical Modelling Contribute to Informed Decision Making?
  86. A network-level explanation for the differences in HIV prevalence in South Africa's racial groups
  87. Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa
  88. Low effectiveness of syndromic treatment services for curable sexually transmitted infections in rural South Africa
  89. Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa
  90. Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when?
  91. Systematic review of orogenital HIV-1 transmission probabilities
  92. Understanding the Impact of Male Circumcision Interventions on the Spread of HIV in Southern Africa
  93. Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics
  94. Understanding the differences between contrasting HIV epidemics in east and west Africa: results from a simulation model of the Four Cities Study
  95. Behaviour change and competitive exclusion can explain the diverging HIV-1 and HIV-2 prevalence trends in Guinea–Bissau
  96. Quantifying HIV-1 transmission due to contaminated injections
  97. HIV incidence and recent injections among adults in rural southwestern Uganda
  98. Empirical Observations Underestimate the Proportion of Human Immunodeficiency Virus Infections Attributable to Sexually Transmitted Diseases in the Mwanza and Rakai Sexually Transmitted Disease Treatment Trials: Simulation Results
  100. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis
  101. Amplified HIV Transmission during Early‐Stage Infection
  102. Determinants of the Impact of Sexually Transmitted Infection Treatment on Prevention of HIV Infection: A Synthesis of Evidence from the Mwanza, Rakai, and Masaka Intervention Trials
  103. Can Population Differences Explain the Contrasting Results of the Mwanza, Rakai, and Masaka HIV/Sexually Transmitted Disease Intervention Trials?
  104. Commentary: What can we make of an association between human immunodeficiency virus prevalence and population mobility?
  105. Comparison of STD prevalences in the Mwanza, Rakai, and Masaka trial populations: the role of selection bias and diagnostic errors
  107. Links between premarital sexual behaviour and extramarital intercourse: a multi-site analysis
  108. Monitoring the AIDS epidemic using HIV prevalence data among young women attending antenatal clinics: prospects and problems